Dongyao Pharmaceutical-B (01875) released its performance for the six months ending June 30, 2024, with a revenue of RMB 0.521 billion, an increase of 58.69% year-on-year. The company's equity holders' attributable profit is RMB 31.559 million, compared to a loss of RMB 15.163 million in the same period last year. Earnings per share is RMB 0.04.
During the period, product sales revenue was RMB 0.4004 billion, an increase of 44% year-on-year, mainly from the core product Bevaci®béta Injection Park made a continuing increase in sales. CDMO/CMO business revenue reached RMB 0.114 billion, an increase of 144% year-on-year. The company's hematopoietic capacity remained robust, with a net cash inflow from operating activities of RMB 27.801 million in the first half of the year, maintaining positive.
The strategic transformation of CDMO has achieved remarkable results, and sales of self-developed products have also steadily increased. It achieved a net income of RMB 31.559 million in the first half of the year, turning a loss into a profit.
